This Revvity webinar showcases how cutting-edge AI, machine learning, and integrated informatics platforms are transforming antibody discovery and developability assessment.
Sponsored by:
On Demand Webinars
Federated Future: Back to the Science of Discovery
Federated Future: Back to the Science of Discovery
This Revvity webinar showcases how cutting-edge AI, machine learning, and integrated informatics platforms are transforming antibody discovery and developability assessment.
Breaking Boundaries in Targeted Protein Degradation
Targeted protein degradation is redefining what’s possible in modern drug discovery. By harnessing the cell’s own machinery to eliminate disease-causing proteins, degraders and molecular glues are moving science beyond traditional inhibition—and into a new era of precision and control.
Al and Multimodal Research: Turning Biological Complexity into Therapeutic Opportunity
Drug discovery is increasingly multimodal, spanning small molecules, antibodies, RNA-based therapies, cell and gene therapies, and novel combinations like ADCs.
The Full Perspective: Al-Driven Antibody Discovery from Design to Development
Antibody drug discovery faces significant challenges in optimizing workflows, reducing timelines, and ensuring the successful development of therapeutic antibodies.
Articles
Beyond algorithms: Building stronger AI foundations for drug discovery
Modern drug discovery produces more data than ever, from genomics and chemical screening to imaging and patient datasets.
From Discovery to Delivery: The Rise of New Modalities
In the rapidly evolving landscape of pharmaceuticals and biotechnology, the emergence of multimodal drug discovery heralds a transformative era, where innovation and strategic foresight are paramount. This evolution is not a scientific leap, but also a technological one, fundamentally reshaping the competitive environment.
The New RNA World: Evolving RNA from Messenger to Versatile Therapeutic
RNA has evolved from a molecular messenger into a powerful and versatile therapeutic tool.
The Evolution of Antibody Drug Discovery: Unlocking Innovation with Bioinformatics and Al
Since monoclonal antibodies (mAbs) were developed and received their first approval, they became indispensable as research tools and biotherapeutic agents.
The Innovation Imperative: Pioneering New Modalities for Therapeutic Leadership
In the rapidly evolving landscape of pharmaceuticals and biotechnology, the emergence of multimodal drug discovery heralds a transformative era for drug discovery, where innovation and strategic Foresight are paramount.
White Papers
New Modalities, New Tools: Choosing a Flexible Digital Platform for Drug Discovery
As pharmaceutical innovation rapidly evolves, the complexity of data generated from RNA therapeutics, gene therapies, antibody-drug conjugates (ADCs), and protein degraders necessitates a new approach to digital infrastructure.
Breaking Boundaries in Drug Discovery: The Rise of Targeted Protein Degraders
Targeted protein degraders like PROTACs, LYTACs, AUTACs, and DACs are redefining modern therapeutics. These tools eliminate disease-causing proteins, even those once considered “undruggable”.They offer new hope for treating cancer, inflammation, and neurodegenerative disorders.
Guidelines
A Scientist’s guide to electronic laboratory notebook selection
Modern drug discovery depends on fast, reliable access to high-quality experimental data. Yet many R&D teams still rely on disconnected systems, manual documentation, or outdated ELNs that cannot keep pace with evolving scientific processes.
A Technology Guide to Integrated Informatics for Scientific Research
Contemporary scientific research reflects a growing focus on complexity and collaboration.
A Technology Guide to Integrated Informatics for Scientific Research
Contemporary scientific research reflects a growing focus on complexity and collaboration.
Brochures
Beyond algorithms: Building stronger AI foundations for drug discovery
Modern drug discovery produces more data than ever, from genomics and chemical screening to imaging and patient datasets.
Building a unified design-make-test-decide approach to drug discovery
The rise of modalities like antibody-drug conjugates (ADCs) and engineered cell therapies has added new layers of complexity to this process.